Fulcrum Therapeutics, Inc.FULCNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank0
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P0
Near historical low
vs 5Y Ago
-0.3x
Contraction
Streak
5 yr
Consecutive declineDecelerating
PeriodValue
2025-21.35%
2024-12.53%
2023-0.06%
202236.63%
202142.65%
202062.74%
201958.11%
201884.80%
20170.00%